- Home
- TSHA vs OPRA Comparison
TSHA vs OPRA Comparison
Compare TSHA & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | OPRA |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | Norway |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TSHA | OPRA |
|---|---|---|
| Price | $6.65 | $20.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $11.63 | ★ $21.50 |
| AVG Volume (30 Days) | ★ 3.6M | 326.4K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.61% |
| EPS Growth | ★ 5.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,773,000.00 | N/A |
| Revenue This Year | N/A | $21.29 |
| Revenue Next Year | $1,152.42 | $15.34 |
| P/E Ratio | ★ N/A | $13.62 |
| Revenue Growth | ★ 17.28 | N/A |
| 52 Week Low | $2.33 | $11.71 |
| 52 Week High | $7.30 | $21.06 |
Technical Indicators
Market Signals| Indicator | TSHA | OPRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 66.13 |
| Support Level | $4.24 | $16.96 |
| Resistance Level | $6.76 | $21.06 |
| Average True Range (ATR) | 0.43 | 0.74 |
| MACD | 0.07 | 0.13 |
| Stochastic Oscillator | 75.27 | 91.44 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
About OPRA Opera Limited
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.